Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
6.6M
Short interest
settlement 2026-10-15
5.1
Days to cover
-1.4 days vs prior
34.8%
Short share of volume
2026-10-28
1,112
Fails to deliver
settlement 2026-09-24
Thu 29 Oct
Next earnings
estimated date
-$399K
Insider flow, 90 days
0 buys, 1 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ALNY is 6,568,786 shares, down 625,311 shares over the last month. Over the last 48 readings it ranged from 2,493,180 shares (28 February 2025) to 7,711,495 shares (30 September 2026). At the reported average volume of 1.3M shares a day that is 5.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/alny" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 6,568,786 | -14.8% | 1,289,127 | 5.10 |
| 2026-09-30 | 7,711,495 | +7.2% | 1,195,107 | 6.45 |
| 2026-09-15 | 7,194,097 | +13.5% | 1,742,234 | 4.13 |
| 2026-08-31 | 6,340,087 | +32.9% | 1,625,574 | 3.90 |
| 2026-08-14 | 4,770,978 | -0.7% | 2,018,399 | 2.36 |
| 2026-07-31 | 4,803,194 | -16.8% | 2,204,446 | 2.18 |
| 2026-07-15 | 5,773,373 | -0.5% | 1,782,477 | 3.24 |
| 2026-06-30 | 5,799,788 | +6.7% | 1,373,085 | 4.22 |
| 2026-06-15 | 5,437,337 | +2.6% | 1,142,712 | 4.76 |
| 2026-05-29 | 5,300,015 | -1.8% | 917,637 | 5.78 |
| 2026-05-15 | 5,398,804 | +13.1% | 1,052,011 | 5.13 |
| 2026-04-30 | 4,773,214 | -5.2% | 1,186,604 | 4.02 |
| 2026-04-15 | 5,034,063 | -0.4% | 983,971 | 5.12 |
| 2026-03-31 | 5,056,408 | +15.7% | 1,262,297 | 4.01 |
| 2026-03-13 | 4,369,615 | -4.4% | 1,045,068 | 4.18 |
| 2026-02-27 | 4,572,652 | -12.8% | 1,025,083 | 4.46 |
| 2026-02-13 | 5,244,475 | -0.7% | 1,872,268 | 2.80 |
| 2026-01-30 | 5,282,136 | -5.1% | 1,442,702 | 3.66 |
| 2026-01-15 | 5,565,961 | +0.6% | 1,496,902 | 3.72 |
| 2025-12-31 | 5,532,159 | +32.2% | 1,911,674 | 2.89 |
| 2025-12-15 | 4,184,652 | +5.7% | 1,310,181 | 3.19 |
| 2025-11-28 | 3,960,190 | -7.5% | 969,124 | 4.09 |
| 2025-11-14 | 4,279,250 | +13.5% | 953,633 | 4.49 |
| 2025-10-31 | 3,769,098 | -5.6% | 1,127,221 | 3.34 |
| 2025-10-15 | 3,993,922 | +13.9% | 1,146,101 | 3.48 |
| 2025-09-30 | 3,507,540 | -5.7% | 1,043,702 | 3.36 |
| 2025-09-15 | 3,718,643 | -6.4% | 1,220,959 | 3.05 |
| 2025-08-29 | 3,973,434 | +15.9% | 1,064,147 | 3.73 |
| 2025-08-15 | 3,426,778 | +5.8% | 1,331,597 | 2.57 |
| 2025-07-31 | 3,238,527 | -4.2% | 1,165,461 | 2.78 |
| 2025-07-15 | 3,379,378 | +1.6% | 894,967 | 3.78 |
| 2025-06-30 | 3,327,381 | -1.4% | 913,715 | 3.64 |
| 2025-06-13 | 3,375,720 | -2.1% | 733,661 | 4.60 |
| 2025-05-30 | 3,448,792 | -6.3% | 1,068,199 | 3.23 |
| 2025-05-15 | 3,681,405 | +16.9% | 1,089,907 | 3.38 |
| 2025-04-30 | 3,149,449 | +2.9% | 787,522 | 4.00 |
| 2025-04-15 | 3,060,597 | +2.4% | 1,304,467 | 2.35 |
| 2025-03-31 | 2,989,679 | +17.8% | 1,171,232 | 2.55 |
| 2025-03-14 | 2,538,284 | +1.8% | 570,850 | 4.45 |
| 2025-02-28 | 2,493,180 | -22.6% | 877,971 | 2.84 |
| 2025-02-14 | 3,218,951 | +9.4% | 669,049 | 4.81 |
| 2025-01-31 | 2,943,280 | -6.6% | 676,021 | 4.35 |
| 2025-01-15 | 3,151,055 | -5.8% | 682,135 | 4.62 |
| 2024-12-31 | 3,346,557 | -4.1% | 614,811 | 5.44 |
| 2024-12-13 | 3,489,237 | +2.8% | 518,284 | 6.73 |
| 2024-11-29 | 3,393,837 | -9.3% | 865,270 | 3.92 |
| 2024-11-15 | 3,739,701 | +1.1% | 944,429 | 3.96 |
| 2024-10-31 | 3,697,098 | -23.6% | 938,551 | 3.94 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of ALNY volume is 34.8%, down 14.5 points over the last five sessions. Over the last 30 readings it ranged from 25.8% (14 October 2026) to 79.2% (22 September 2026). The latest reading is 16.8 points below the 30-session average of 51.6%, on 822K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 287K | 822K | 34.8% | 529 |
| 2026-10-27 | 339K | 767K | 44.2% | 26 |
| 2026-10-26 | 176K | 612K | 28.7% | 434 |
| 2026-10-23 | 184K | 404K | 45.6% | 159 |
| 2026-10-22 | 311K | 978K | 31.8% | 0 |
| 2026-10-21 | 238K | 482K | 49.4% | 4 |
| 2026-10-20 | 307K | 665K | 46.2% | 317 |
| 2026-10-19 | 183K | 562K | 32.6% | 79 |
| 2026-10-16 | 246K | 607K | 40.5% | 82 |
| 2026-10-15 | 163K | 543K | 30.0% | 84 |
| 2026-10-14 | 114K | 442K | 25.8% | 395 |
| 2026-10-13 | 170K | 493K | 34.4% | 2,469 |
| 2026-10-12 | 202K | 414K | 48.8% | 2,177 |
| 2026-10-09 | 183K | 402K | 45.6% | 0 |
| 2026-10-08 | 310K | 701K | 44.3% | 8,040 |
| 2026-10-07 | 213K | 439K | 48.5% | 0 |
| 2026-10-06 | 279K | 645K | 43.3% | 2,191 |
| 2026-10-05 | 265K | 543K | 48.8% | 71 |
| 2026-10-02 | 329K | 618K | 53.1% | 7 |
| 2026-10-01 | 579K | 979K | 59.1% | 126 |
| 2026-09-30 | 184K | 345K | 53.3% | 2,400 |
| 2026-09-29 | 229K | 311K | 73.7% | 0 |
| 2026-09-28 | 317K | 483K | 65.5% | 0 |
| 2026-09-25 | 298K | 410K | 72.7% | 66 |
| 2026-09-24 | 291K | 388K | 75.0% | 320 |
| 2026-09-23 | 327K | 482K | 67.9% | 2 |
| 2026-09-22 | 342K | 432K | 79.2% | 1 |
| 2026-09-21 | 388K | 504K | 77.0% | 0 |
| 2026-09-18 | 460K | 626K | 73.5% | 0 |
| 2026-09-17 | 270K | 360K | 75.0% | 3 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 24 September 2026, the fails-to-deliver balance in ALNY is 1,112 shares, down 4 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (11 May 2026) to 22,234 shares (12 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-24 | 1,112 | $246.51 | $274K |
| 2026-09-23 | 1,116 | $251.65 | $281K |
| 2026-09-22 | 1,379 | $244.32 | $337K |
| 2026-09-21 | 100 | $239.56 | $24K |
| 2026-09-15 | 159 | $249.99 | $40K |
| 2026-08-26 | 3 | $240.08 | $720 |
| 2026-08-21 | 297 | $229.30 | $68K |
| 2026-08-20 | 19,753 | $242.61 | $4.8M |
| 2026-08-12 | 2 | $221.20 | $442 |
| 2026-08-05 | 16 | $219.00 | $4K |
| 2026-07-31 | 65 | $205.48 | $13K |
| 2026-07-28 | 100 | $278.40 | $28K |
| 2026-07-16 | 8 | $279.14 | $2K |
| 2026-07-13 | 4 | $298.76 | $1K |
| 2026-07-09 | 3,683 | $323.50 | $1.2M |
| 2026-07-08 | 3,745 | $321.59 | $1.2M |
| 2026-07-01 | 3,004 | $301.03 | $904K |
| 2026-06-22 | 6 | $278.09 | $2K |
| 2026-06-18 | 4 | $282.72 | $1K |
| 2026-06-12 | 22,234 | $289.39 | $6.4M |
| 2026-06-09 | 75 | $292.16 | $22K |
| 2026-06-08 | 6,664 | $303.05 | $2.0M |
| 2026-06-05 | 6,912 | $303.64 | $2.1M |
| 2026-05-12 | 18,560 | $284.84 | $5.3M |
| 2026-05-11 | 1 | $295.05 | $295 |
| 2026-05-07 | 14 | $303.00 | $4K |
| 2026-04-24 | 15 | $313.79 | $5K |
| 2026-04-14 | 3 | $333.00 | $999 |
| 2026-04-10 | 598 | $321.28 | $192K |
| 2026-04-08 | 489 | $319.52 | $156K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ALNY reported 1 open-market sell worth $399K in the last 90 days and no open-market buys. Latest filing: SUPRAN BRYAN (EVP, CLO and Secretary) on 2026-10-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | SUPRAN BRYAN | EVP, CLO and Secretary | Sell | 2K | $226.88 | $399K | 13K |
| 2026-09-19 | Greenstreet Yvonne | Chief Executive Officer | Grant | 107 | $0.00 | $0 | 96K |
| 2026-06-01 | PYOTT DAVID E I | Director | Sell | 17 | $302.65 | $5K | 2K |
| 2026-06-01 | PYOTT DAVID E I | Director | Sell | 495 | $300.72 | $149K | 2K |
| 2026-06-01 | PYOTT DAVID E I | Director | Sell | 1K | $299.87 | $366K | 2K |
| 2026-06-01 | PYOTT DAVID E I | Director | Sell | 1K | $298.91 | $351K | 3K |
| 2026-06-01 | PYOTT DAVID E I | Director | Sell | 921 | $297.71 | $274K | 4K |
| 2026-06-01 | PYOTT DAVID E I | Director | Exercise or conversion | 4K | $0.00 | $0 | 5K |
| 2026-05-20 | Sigal Charles Elliott | Director | Grant | 671 | $0.00 | $0 | 1K |
| 2026-05-20 | SCHULMAN AMY W | Director | Grant | 838 | $0.00 | $0 | 24K |
| 2026-05-20 | Reitan Colleen F | Director | Grant | 671 | $0.00 | $0 | 1K |
| 2026-05-20 | PYOTT DAVID E I | Director | Grant | 671 | $0.00 | $0 | 2K |
| 2026-05-20 | KELLOGG PETER N | Director | Grant | 671 | $0.00 | $0 | 1K |
| 2026-05-20 | HAMBURG MARGARET A | Director | Grant | 671 | $0.00 | $0 | 2K |
| 2026-05-20 | BRANDICOURT OLIVIER | Director | Grant | 671 | $0.00 | $0 | 1K |
| 2026-05-20 | Ausiello Dennis A | Director | Grant | 671 | $0.00 | $0 | 2K |
| 2026-05-20 | Arbuckle Stuart A | Director | Grant | 671 | $0.00 | $0 | 671 |
| 2026-05-13 | SCHULMAN AMY W | Director | Exercise or conversion | 11K | $70.20 | $790K | 23K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 199 | $333.94 | $66K | 9K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 293 | $331.89 | $97K | 10K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 829 | $330.46 | $274K | 10K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 909 | $329.76 | $300K | 11K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 56 | $320.14 | $18K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 8 | $325.49 | $3K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 81 | $323.64 | $26K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 245 | $322.86 | $79K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 224 | $321.64 | $72K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 147 | $320.62 | $47K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 86 | $319.69 | $27K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 209 | $318.47 | $67K | 13K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 359 | $317.44 | $114K | 13K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 265 | $316.61 | $84K | 13K |
| 2026-03-05 | Garg Pushkal | EVP Chief R&D | Sell | 500 | $326.08 | $163K | 19K |
| 2026-03-05 | Garg Pushkal | EVP Chief R&D | Sell | 510 | $324.59 | $166K | 19K |
| 2026-03-05 | Garg Pushkal | EVP Chief R&D | Sell | 740 | $323.55 | $239K | 20K |
| 2026-03-05 | Garg Pushkal | EVP Chief R&D | Sell | 654 | $322.33 | $211K | 20K |
| 2026-03-05 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 153 | $326.24 | $50K | 21K |
| 2026-03-05 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 148 | $324.60 | $48K | 21K |
| 2026-03-05 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 233 | $323.25 | $75K | 21K |
| 2026-03-05 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 124 | $321.81 | $40K | 21K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 208 | $325.67 | $68K | 21K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 272 | $324.88 | $88K | 21K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 767 | $323.84 | $248K | 22K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 350 | $323.01 | $113K | 22K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 289 | $321.82 | $93K | 23K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 215 | $320.81 | $69K | 23K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 102 | $320.01 | $33K | 23K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 106 | $319.03 | $34K | 23K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 265 | $325.67 | $86K | 96K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 345 | $324.88 | $112K | 96K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 973 | $323.84 | $315K | 96K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 444 | $323.01 | $143K | 97K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 368 | $321.82 | $118K | 98K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 274 | $320.81 | $88K | 98K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 129 | $320.01 | $41K | 98K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 135 | $319.03 | $43K | 98K |
| 2026-03-04 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 223 | $325.67 | $73K | 62K |
| 2026-03-04 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 291 | $324.88 | $95K | 62K |
| 2026-03-04 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 818 | $323.84 | $265K | 62K |
| 2026-03-04 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 374 | $323.01 | $121K | 63K |
| 2026-03-04 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 309 | $321.82 | $99K | 64K |
| 2026-03-04 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 230 | $320.81 | $74K | 64K |
| 2026-03-04 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 109 | $320.01 | $35K | 64K |
| 2026-03-04 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 114 | $319.03 | $36K | 64K |
| 2026-03-04 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 208 | $325.67 | $68K | 34K |
| 2026-03-04 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 272 | $324.88 | $88K | 35K |
| 2026-03-04 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 767 | $323.84 | $248K | 35K |
| 2026-03-04 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 350 | $323.01 | $113K | 36K |
| 2026-03-04 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 289 | $321.82 | $93K | 36K |
| 2026-03-04 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 215 | $320.81 | $69K | 36K |
| 2026-03-04 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 102 | $320.01 | $33K | 36K |
| 2026-03-04 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 106 | $319.03 | $34K | 37K |
| 2026-03-04 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 57 | $325.67 | $19K | 21K |
| 2026-03-04 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 75 | $324.88 | $24K | 21K |
| 2026-03-04 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 210 | $323.84 | $68K | 21K |
| 2026-03-04 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 96 | $323.01 | $31K | 22K |
| 2026-03-04 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 79 | $321.82 | $25K | 22K |
| 2026-03-04 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 59 | $320.81 | $19K | 22K |
| 2026-03-04 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 28 | $320.01 | $9K | 22K |
| 2026-03-04 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 29 | $319.03 | $9K | 22K |
| 2026-03-03 | Garg Pushkal | EVP Chief R&D | Sell | 463 | $321.50 | $149K | 23K |
| 2026-03-03 | Garg Pushkal | EVP Chief R&D | Sell | 640 | $320.48 | $205K | 24K |
| 2026-03-03 | Garg Pushkal | EVP Chief R&D | Sell | 317 | $319.06 | $101K | 25K |
| 2026-03-03 | Garg Pushkal | EVP Chief R&D | Sell | 355 | $316.74 | $112K | 25K |
| 2026-03-03 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 359 | $321.58 | $115K | 22K |
| 2026-03-03 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 722 | $320.51 | $231K | 22K |
| 2026-03-03 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 282 | $318.62 | $90K | 23K |
| 2026-03-03 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 289 | $316.55 | $91K | 23K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 53 | $332.64 | $18K | 64K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 129 | $331.93 | $43K | 64K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 112 | $330.85 | $37K | 64K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 234 | $329.71 | $77K | 65K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 138 | $328.71 | $45K | 65K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 454 | $327.67 | $149K | 65K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 541 | $326.81 | $177K | 65K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 356 | $325.63 | $116K | 66K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 124 | $324.65 | $40K | 66K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 65 | $323.62 | $21K | 66K |
| 2026-03-02 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Grant | 5K | $0.00 | $0 | 66K |
| 2026-03-02 | Garg Pushkal | EVP Chief R&D | Sell | 42 | $332.64 | $14K | 25K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON13 Form 144 notices on file for ALNY worth $25.9M at the prices reported; 1 in the last 90 days worth $399K. Latest: SUPRAN BRYAN filed on 2026-10-02 to sell 1,758 shares ($399K) from 2026-10-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-02 | SUPRAN BRYANOfficer | 2K | $399K | 0.001% | 2026-10-02 | Fidelity Brokerage Services LLC |
| 2026-06-01 | PYOTT DAVID E IDirector | 4K | $1.1M | 0.003% | 2026-06-01 | UBS Financial Services, Inc. |
| 2026-04-06 | McLaughlin MelissaOfficer | 2K | $732K | 0.002% | 2026-04-06 | UBS Financial Services, Inc. |
| 2026-03-05 | Fitzgerald Kevin JosephOfficer | 658 | $213K | 0.000% | 2026-03-05 | UBS Financial Services, Inc. |
| 2026-03-05 | Garg PushkalOfficer | 2K | $778K | 0.002% | 2026-03-05 | UBS Financial Services, Inc. |
| 2026-03-03 | Fitzgerald Kevin JosephOfficer | 2K | $531K | 0.001% | 2026-03-03 | UBS Financial Services, Inc. |
| 2026-03-03 | Garg PushkalOfficer | 2K | $570K | 0.001% | 2026-03-03 | UBS Financial Services, Inc. |
| 2026-02-27 | Garg PushkalOfficer | 5K | $1.5M | 0.003% | 2026-02-27 | UBS Financial Services, Inc. |
| 2026-02-17 | Fitzgerald Kevin JosephOfficer | 2K | $678K | 0.002% | 2026-02-17 | UBS Financial Services, Inc. |
| 2026-01-13 | Fitzgerald Kevin JosephOfficer | 2K | $845K | 0.002% | 2026-01-13 | UBS Financial Services, Inc. |
| 2025-11-17 | Fitzgerald Kevin JosephOfficer | 12K | $5.4M | 0.009% | 2025-11-17 | UBS Financial Services, Inc. |
| 2025-11-12 | Greenstreet YvonneOfficer, Director | 26K | $11.6M | 0.019% | 2025-11-12 | UBS Financial Services, Inc. |
| 2025-10-03 | Garg PushkalOfficer | 3K | $1.4M | 0.002% | 2025-10-03 | UBS Financial Services, Inc. |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of ALNY in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 11.0% of the class (14,640,525 shares), filed 2026-05-06 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-14 | 13G/Ano. 3 | Capital World Investorsinvestment adviser | 10.9M | 8.2% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 1 | Capital Research Global Investorsinvestment adviser | 9.5M | 7.1% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 23 | FMR LLCparent holding company | 14.6M | 11.0% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 23 | Abigail P. Johnsonindividual | 14.6M | 11.0% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 7.1M | 5.3% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 10 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding ALNY at their latest 13F. JSON7 of the 30 tracked managers held ALNY at their latest 13F, $1.30B in total at quarter-end prices. Two Sigma Investments is the largest at $564.7M (0.4% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.9M | $564.7M | 0.41% | -117K |
| D. E. Shaw & Co. | 2026-06-30 | 1.1M | $332.4M | 0.16% | +45K |
| AQR Capital Management | 2026-06-30 | 728K | $219.0M | 0.08% | -185K |
| Millennium Management | 2026-06-30 | 316K | $95.1M | 0.03% | -132K |
| Citadel Advisors | 2026-06-30 | 191K | $57.5M | 0.01% | +168K |
| Bridgewater Associates | 2026-06-30 | 100K | $30.0M | 0.12% | -7K |
| Fisher Asset Management | 2026-06-30 | 6K | $1.9M | 0.00% | +207 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Alnylam Pharmaceuticals reported revenue of $1.29B, up 66.9% from the same quarter a year earlier, and net income of $164.5M (1.21 diluted EPS). In FY 2025 it generated $524.1M of operating cash flow.
- Cash
- $1.71B
- Equity
- $1.35B
- Total assets
- $5.56B
- Shares outstanding
- 133,809,118
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $1.29B | $164.5M | 12.7% | 1.21 |
| Q1 FY 2026 | 2026-03-31 | n/a | $206.0M | n/a | n/a |
| Q4 FY 2025derived | 2025-12-31 | n/a | $153.1M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $1.25B | $251.1M | 20.1% | 1.84 |
| Q2 FY 2025 | 2025-06-30 | $773.7M | -$72.2M | -9.3% | -0.55 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$18.3M | n/a | n/a |
| Q4 FY 2024derived | 2024-12-31 | $593.2M | -$83.8M | -14.1% | n/a |
| Q3 FY 2024 | 2024-09-30 | $500.9M | -$111.6M | -22.3% | -0.87 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $3.71B | $313.7M | $524.1M | $58.7M | n/a | n/a |
| FY 2024 | 2024-12-31 | $2.25B | -$278.2M | -$8.3M | $34.3M | n/a | n/a |
| FY 2023 | 2023-12-31 | $1.83B | -$440.2M | $104.2M | $62.2M | n/a | n/a |
| FY 2022 | 2022-12-31 | $1.04B | -$1.13B | -$541.3M | $72.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | $844.3M | -$852.8M | -$641.7M | $76.4M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-24 from the cover page.
What this page is
Alnylam Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Alnylam Pharmaceuticals (ALNY), SEC CIK 1178670, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-24.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-04-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 1178670Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of ALNY is sold short?
6,568,786 shares were held short at the 2026-10-15 settlement, 5.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ALNY's daily short volume?
On 2026-10-28, 286,543 of the 822,464 ALNY shares reported to FINRA were sold short, 34.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ALNY have fails to deliver?
The SEC's latest file shows 1,112 ALNY shares failed to deliver at settlement 2026-09-24. Fails are reported per settlement date and published twice a month with a lag.
Are ALNY insiders buying or selling?
Insiders at ALNY reported 1 open-market sell worth $399K in the last 90 days and no open-market buys. Latest filing: SUPRAN BRYAN (EVP, CLO and Secretary) on 2026-10-02.
Have ALNY insiders filed to sell?
13 Form 144 notices on file for ALNY worth $25.9M at the prices reported; 1 in the last 90 days worth $399K. Latest: SUPRAN BRYAN filed on 2026-10-02 to sell 1,758 shares ($399K) from 2026-10-02.
Who owns 5% or more of ALNY?
5 holders report 5% or more of ALNY in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 11.0% of the class (14,640,525 shares), filed 2026-05-06 for an event on 2026-03-31.
What did ALNY report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Alnylam Pharmaceuticals reported revenue of $1.29B, up 66.9% from the same quarter a year earlier, and net income of $164.5M (1.21 diluted EPS). In FY 2025 it generated $524.1M of operating cash flow.
Which tracked 13F managers own ALNY?
7 of the 30 tracked 13F managers held ALNY shares at their latest filing, $1.30B in all. The largest: Two Sigma Investments (1.9M shares, $564.7M), D. E. Shaw & Co. (1.1M shares, $332.4M), Cliff Asness's AQR Capital Management (728K shares, $219.0M), Izzy Englander's Millennium Management (316K shares, $95.1M), Ken Griffin's Citadel Advisors (191K shares, $57.5M), Ray Dalio's Bridgewater Associates (100K shares, $30.0M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.